Kura Oncology price target raised to $37 from $32 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Kura Oncology (KURA) to $37 from $32 and keeps a Buy rating on the shares. The Kyowa agreement allows ziftomenib’s expansive development in frontline settings and beyond, the analyst tells investors in a research note. The firm says Kura is eligible to receive tiered double-digit royalties on outside th U.S. net product sales.